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Introduction
Head and neck squamous cell carcinoma (HNSCC) is the 
sixth most common cancer worldwide with an approximate 50% 
five-year survival rate.1 Two groups that independently studied 
the genetic origins of HNSCC reported inactivating mutations 
in NOTCH1.1,2 This was the first strong evidence of NOTCH1 
mutations in solid tumors; analysis of the mutations suggested 
that NOTCH1 might act as a tumor suppressor gene (TSG) in 
HNSCC.1,2 Notwithstanding this important finding, and con-
trary to original expectations, these and other detailed analyses 
of HNSCC did not uncover a great number of recurrent somatic 
mutations in novel genes.3,4
The number of known mutations and specific mutational 
hotspots in HNSCC tumors only partially explains their biologi-
cal complexity and limits the development of novel diagnostic 
markers and therapeutic agents. TP53 was again identified as the 
most commonly mutated gene in HNSCC and, while mutant 
TP53 has been associated with poor survival,5 the most impor-
tant biologic consequences of this alteration have been elusive. 
Moreover, it was also known that overall and disease-specific sur-
vival is higher in patients with HPV-associated HNSCC tumors,6 
and that this distinct molecular and pathologic subtype displays 
an average of 4 somatic mutations per tumor, while HPV-negative 
HNSCC tumors harbor 20.1 HPV-associated HNSCCs have 
a distinctly different molecular landscape from HPV-negative 
HNSCCs. TP53 is rarely identified as mutated in HPV-positive 
HNSCC patients because the HPV E6 oncoprotein silences 
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integration analysis
Tumor suppressor genes (TsGs) are commonly inactivated by somatic mutation and/or promoter methylation; yet, 
recent high-throughput genomic studies have not identified key TsGs inactivated by both mechanisms. We pursued an 
integrated molecular analysis based on methylation binding domain sequencing (MBD-seq), 450K Methylation arrays, 
whole exome sequencing, and whole genome gene expression arrays in primary head and neck squamous cell car-
cinoma (hNscc) tumors and matched uvulopalatopharyngoplasty tissue samples (UPPPs). We uncovered 186 down-
regulated genes harboring cancer specific promoter methylation including PAX1 and PAX5 and we identified 10 key 
tumor suppressor genes (GABRB3, HOXC12, PARP15, SLCO4C1, CDKN2A, PAX1, PIK3AP1, HOXC6, PLCB1, and ZIC4) inactivated 
by both promoter methylation and/or somatic mutation. among the novel tumor suppressor genes discovered with dual 
mechanisms of inactivation, we found a high frequency of genomic and epigenomic alterations in the PAX gene family 
of transcription factors, which selectively impact canonical NOTCH and TP53 pathways to determine cell fate, cell survival, 
and genome maintenance. Our results highlight the importance of assessing TsGs at the genomic and epigenomic level 
to identify key pathways in hNscc, deregulated by simultaneous promoter methylation and somatic mutations.
1032 epigenetics Volume 9 Issue 7
TP53, protecting the cells from apoptosis and senescence, while 
the HPV E7 oncoprotein deregulates the cell cycle.7,8 CDKN2A, 
a principal cyclin-dependent kinase inhibitor that decelerates 
the cell cycle, is lost in HPV-negative HNSCC9 and amplified 
in HPV-positive HNSCC.10 HNSCCs also exhibit many chro-
mosomal abnormalities, including amplifications of the 11q13 
region containing the cyclin D1 gene and the 7p11 region encod-
ing EGFR, which lead to proto-oncogene activation.1
Aberrant DNA methylation of CpGs in the proximity of pre-
dicted transcription start sites (TSS) often leads to alterations 
in gene function and pathway deregulation in human cancer. 
Epigenetic events linked to TSG inactivation through promoter 
methylation, are more frequent events than somatic mutations 
in cancer, and may be driving tumorigenic initiation and pro-
gression. Promoter methylation of CDK2NA, HOXA9, NID2, 
EDNRB, KIF1A, and DCC have previously been identified and 
characterized in HNSCC.11-13
To date, recent high-throughput methylation studies14,15 have 
not focused on the relative contribution of TSGs inactivation by 
DNA methylation and somatic mutations in oncogenesis and 
may have severely underestimated the true frequency of inactiva-
tion of key TSGs and signaling pathways. We tested the hypoth-
esis that TSG promoter methylation predominantly occurs in 
genes or pathways with well-known somatic mutations and/or 
deletions in most HNSCC tumors, including TP53, CDK2NA,16 
and, more recently, NOTCH11,2 and FAT1,17 as well as in recently 
described genes with low frequency mutations.18
Results
Patient selection
One hundred and eight (108) head and neck squamous cell 
carcinoma (HNSCC) and 35 uvulopalatopharyngealplasty 
(UPPP) patients were consented for this study at Johns Hopkins 
Medical Institutions hospitals and MD Anderson Cancer Center. 
The study was approved by the Ethics Committee of each par-
ticipating hospital, as well as by the Johns Hopkins Institutional 
Review Board. The 143 samples were divided into Discovery 
and Prevalence cohorts. The Discovery cohort consisted of 32 
HNSCC and 16 UPPP samples. The Prevalence cohort consisted 
of 76 HNSCC and 19 UPPP samples. The 32 tumor samples 
selected for the Discovery cohort were accrued in Hopkins 
(n=17) and in MD Anderson (n=15). The 35 UPPP samples were 
accrued at Hopkins.
Johns Hopkins component
Fresh-frozen surgically resected HNSCC (n = 93) and UPPPP 
(n = 35) tissue samples were obtained from patients at Johns 
Hopkins Medical Institutions in Baltimore. HNSCC tissue was 
analyzed by frozen section histology to estimate neoplastic cel-
lularity. In order to enrich the samples for neoplastic cells, nor-
mal tissue was removed from the samples using macro-dissection 
based on the frozen section histology. HPV tumor status was 
determined for oropharyngeal tumors per standard clinical care 
using in situ hybridization. Hybridization was performed using 
the HPV III Family16 probe set that captures HPV genotypes 
16, 18, 33, 35, 45, 51, 52, 56, and 66. HPV16-positive controls 
included an HPV16-positive oropharyngeal cancer and the SiHa 
and CaSki cell lines. HPV tumor status was also determined by 
E6/E7 PCR primer amplification.
MD Anderson component
Fresh-frozen surgically resected tumor samples (n = 15) were 
obtained from consented patients treated for HNSCC at the 
University of Texas MD Anderson Cancer Center, under an 
Institutional Review Board approved protocol. Frozen tissue was 
embedded in optimal cutting temperature compound and cryo-
sections from the top and middle of specimens were stained with 
hematoxylin and eosin prior to being evaluated by a patholo-
gist for the presence of >60% tumor nuclei content or absence 
of tumor (i.e., normal). Samples that passed this criterion were 
sectioned all the way through and washed once in PBS prior to 
isolating genomic DNA using an ArchivePure DNA purification 
kit.
Table 1 describes the clinical attributes of the combined 143 
patient samples from the Discovery and Validation cohorts, 
as well as of the 289 samples from The Cancer Genome Atlas 
that were used to confirm the TP53mut/PAX5 met and the 
NOTCH1mut/PAX1met associations. The 32 HNSCC patient 
samples selected for Discovery in this epigenetic study were the 
same used by Agrawal et al. for the genetic study of HNSCC1. 
This study design allowed us to analyze mutation, methyla-
tion, and expression data from the same HNSCC patients. We 
queried the methylome of these 32 HNSCC patients and fre-
quency matched 16 UPPP normal controls using the Human 
Methylation 450K Beadchip (Illumina). However, the HNSCC 
transcriptome was queried with different platforms. In Hopkins 
the GeneST1.0 arrays (Affymetrix) were used to query the 
HNSCC and UPPP transcriptome and in MD Anderson they 
queried the HNSCC transcriptome with the Human Exon 1.0ST 
arrays (Affymetrix). The integrated methylation/mRNA expres-
sion analysis we are reporting was performed using transcriptome 
data from the 32 samples (16 HNSCC and 16 UPPP) accrued at 
Hopkins because we did not find a satisfactory method of com-
bining GeneST1.0 and Human Exon 1.0ST array data. Nor did 
we have transcriptome and methylome data from normal patient 
samples collected at MD Anderson to compare with the results 
obtained with patients accrued at Hopkins.
Characterization of the HNSCC methylome using MBD-seq
In the first part of our study, we used a methylated DNA 
binding domain based sequencing (MBD-seq) approach similar, 
in principle, to what has been previously described,19 but with 
significant modifications (Fig. 1). This analysis was performed 
on a subset of tumors from the same Discovery Cohort in which 
Agrawal et al. discovered and mapped mutations in HNSCC,1 
comprising ten patients and ten frequency matched normal con-
trols (uvulopalatopharyngoplasty tissue samples [UPPP]). The 
ten tumor samples were obtained before chemotherapy or radia-
tion treatment, ensuring that the changes we identified are truly 
reflective of tumor biology, and were micro-dissected to achieve 
a neoplastic cellularity of greater than 60%. Following MBD-
seq, an average of 48.9 million 50 bp reads was obtained for each 
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sample, with an average of 68% of these reads aligning to the 
hg19 genome, 67% of which were aligning uniquely (Data set 1).
Our purpose was to study alterations in the promoter region 
of TSGs and for this study we focused on the “greater promoter,” 
a region that encompasses the well-studied proximal promoter 
that harbors CpG Islands (1500 bases up and downstream from 
the TSS) and the distal promoter (6000 bp upstream of the TSS), 
which includes recently identified CpG Island Shores20 and 
Shelves (Fig. 2A).21 (From this point on, wherever the term pro-
moter is used it refers to the greater promoter region as defined 
here).
We used two independent and highly validated analytical 
approaches, model-based analysis of ChIP-seq (MACS)22 and 
Bump hunting,23 to identify methylation changes across the 
HNSCC genome. MACS identified 9648 alterations, 60% of 
which were gains in methylation events (Fig. 2B). The vast major-
ity of the methylome changes identified by MACS (73%) were 
observed outside of the promoter region. Within the promoter 
region, we observed mostly (89%) gain of methylation events. 
The majority of the methylation loss identified by MACS (93%) 
occurred outside the promoter region. These genome-wide meth-
ylation motifs were integrated with the differentially methylated 
regions (DMRs) identified by Bump hunting to obtain the first 
detailed next-gen analysis of the HNSCC promoter methylome 
(Data set 2; Tables S1 and S2).
Confirmation of methylated sites using 450K arrays and 
integration with expression arrays
To validate the MBD-seq results, we evaluated 
genome-wide differential methylation with the Infinium 
HumanMethylation450K Beadchip (450K array) in 41 cancer 
(including the 10 samples sequenced with MBD-seq) and 16 
UPPP samples. The intersection of genome-wide methylation 
sequencing and methylation array screens uncovered 316 genes, 
which harbor promoter methylation in HNSCC (Table S3). To 
determine the extent of correlation between differential meth-
ylation and mRNA expression patterns, we performed mRNA 
expression microarray analysis (Affymetrix Gene ST 2.0) using 
16 tumor and 16 UPPP samples from the samples included in the 
cohort analyzed with the 450K array platform. We found close 
to 60% concordance between concurrent greater promoter meth-
ylation and gene downregulation. 186 methylated genes were 
found to harbor methylation and downregulation; PAX1 and 
PAX5 exhibited the greatest expression loss (Fig. 3A; Table S4A). 
Table S4B shows the relationship between methylation frequency 
Table 1. summary of clinical attributes of samples in Discovery, Prevalence, and TcGa cohorts
Discovery Prevalence TCGA
Normal HPV+ HPV- Normal HPV+ HPV- HPV+ HPV-
(n = 16) (n = 3) (n = 29) (n = 19) (n = 4) (n = 72) (n = 35) (n = 244)
Sex
Male 9(56%) 3(100%) 18(62%) 14(74%) 3(75%) 52(72%) 31(89%) 172(70%)
Race
Non-Latino White 9(56%) 3(100%) 22(76%) 11(58%) 3(75%) 62(86%) 33(94%) 209(86%)
african american/
Black
7(44%) 0 4(14%) 7(37%) 1(25%) 7(10%) 2(6%) 24(10%)
Other 0 0 3(10%) 1(5%) 0 3(4%) 0 11(5%)
Smoking
Yes 0 1(33%) 23(79%) 0 2(50%) 26(38%) 25(75%) 195(80%)
No 16(100%) 2(67%) 6(21%) 19(100%) 2(50%) 12(18%) 10(29%) 41(17%)
Unknown 0 0 0 0 34(47%) 0 8(3%)
Tumor Site
Oral cavity 0 25(86%) 0 35(49%) 12(34%) 160(66%)
Oropharynx 3(100%) 2(7%) 3(75%) 21(29%) 21(60%) 12(5%)
Larynx 0 2(7%) 0 10(14%) 1(3%) 71(29%)
hypopharynx 0 0 0 4(5%) 1(3%) 1(0.4%)
Unknown 0 0 1(25%) 2(3%) 0 0
T stage
I 0 1(4%) 0 0 3(9%) 17(7%)
II 3(100%) 6(21%) 0 1(1%) 10(29%) 63(26%)
III 0 12(41%) 0 2(3%) 2(6%) 54(22%)
IV 0 9(31%) 4(100%) 63(88%) 9(26%) 87(36%)
Unknown 0 1(4%) 0 6(8%) 11(31%) 23(9%)
1034 epigenetics Volume 9 Issue 7
of the significantly downregulated candidate genes with FC 
< –2 and the expression levels of these candidate genes for the 
16 tumor samples queried with mRNA arrays in the Discovery 
cohort. We have also included Figure S1 to show the expression 
level box plots for these candidate genes in the 16 HNSCC and 
16 UPPP samples queried in the Discovery cohort.
Integration of promoter methylation with somatic mutation 
profiles
We subsequently intersected the promoter methylome with the 
mutational landscape of HNSCC1 and identified concurrent pro-
moter methylation and somatic mutations in ten tumor suppres-
sor genes: GABRB3, HOXC12, PARP15, SLCO4C1, CDKN2A, 
PAX1, PIK3AP1, HOXC6, PLCB1, and ZIC4 (Fig. 3B). CDKN2A 
(p16), one of the most frequently altered tumor suppressor genes 
in human cancer by mutation, methylation, and/or deletion was 
confirmed on this list. The rest of the genes displayed a very low 
mutation frequency in HNSCC, together with frequent inactiva-
tion by promoter methylation.
Unbiased genome-wide and gene set enrichment analyses
Unbiased genome-wide analyses were performed to visualize 
and interpret the large amount of data produced by the sequenc-
ing and microarray experiments. Unsupervised hierarchical 
clustering of the differential methylation events in HNSCC 
revealed a genome-wide loss of methylation. More than half of 
the genes in cancer have lost methylation when compared with 
normal samples at the genome-wide level. This massive loss of 
methylation often suggests the acquisition of plasticity and de-
differentiation associated with stem cells24 (Fig. S2A), together 
with specific gains in promoter methylation (Fig. S2B). To bet-
ter understand the relationship between genome-wide DNA 
methylation loss and copy number alterations we examined the 
correlation between genome-wide DNA methylation frequency 
and copy number alterations. The Spearman correlation coeffi-
cient between methylation frequency and copy number loss was 
0.02. The Spearman correlation coefficient between methylation 
frequency and copy number gain was –0.004. The lack of cor-
relation between DNA methylation and genomic aberrations in 
genes for which both methylome and copy number alterations 
are available in the Discovery cohort can be seen in Table S5. 
The genome-wide DNA methylation and genomic aberrations 
in tumor samples for which both methylome and copy number 
alterations are available in the Discovery cohort can be seen in 
Figure S3.
Analysis of Functional Annotation (AFA)25 was then used to 
integrate the HNSCC methylation, mutation, and expression 
landscapes and detect alterations in cellular signaling pathways, 
protein-protein interaction networks, and gene ontology (GO) 
in HNSCC. AFA revealed that pathways involved in develop-
ment, differentiation, adhesion, proliferation, and biological/
cellular/transcriptional regulation are impacted by concurrent 
promoter methylation, mutations, and differential gene expres-
sion in HNSCC (Figs. S4 and S5; Table S6). AFA also showed 
Figure 1. Representation of the workflow of the study. The figure ascribes all the platforms and techniques used in the discovery and the two indepen-
dent validation sets. The number of samples recruited its time are also depicted in brackets.
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Figure 2. (A) Illustration defining the Greater Promoter region. Using a functional genomic distribution viewpoint we define five cpG genomic locations 
in relation to their distance to the Transcription start site: Proximal promoter, distal promoter, first exon, gene body and intergenic locations. From a 
cpG content and neighborhood context viewpoint we define four cpG genomic locations in relation to their distance to the nearest cpG Island: cpG 
Island, cpG Island shore, cpG Island shelf, Open sea and Gene Body. The Greater promoter window is fixed in relation to the Tss. Therefore, the location 
of cpG Islands will influence the number of significant sequencing reads and 450K probes per gene that are included in our analysis; (B) Workflow for 
identification of differential methylation in the greater promoter of hNscc, using next-generation MBD-sequencing and 450K methylation platforms. 
schematic description of the analytic pipeline developed to unveil the hNscc methylome. This pipeline enriches for mean genome-wide differences in 
cpG methylation as also for genome-wide differences in cpG methylation variability at each chromosomal location, for both, methylation sequencing 
and methylation 450K array data.
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that pathways involved in immune system development, and cell 
differentiation, proliferation, growth and renewal are impacted 
by concurrent epigenetic and genetic alterations in HNSCC 
(Fig. S6).
Methylation-Mutations Interactions with Risk Factors in 
the Discovery Cohort
When attempting to search for any associations between 
the mutated and/or methylated genes and HNSCC risk fac-
tors (TP53 mutations, HPV status, and smoking history) in 
the Discovery Cohort, we observed interesting patterns for the 
PAX1 and PAX5 genes. PAX1 was methylated in all HPV nega-
tive tumors whereas zero methylation events of this gene were 
observed in HPV positive tumors. PAX1 was also methylated in 
most patients with a history of tobacco exposure (71%), while 
only 33% of patients without tobacco exposure history exhibited 
PAX1 methylation. Most HPV negative tumors (83%) showed 
PAX5 methylation compared with 25% of HPV positive tumors. 
On the contrary, tumors from patients with a history of tobacco 
exposure (57%) had similar frequency of PAX5 methylation 
to patients with no smoking history (67%). We also observed 
concurrent genomic and epigenomic associations with viral and 
tobacco exposures. Patients with TP53 mutations also had PAX1 
promoter methylation, history of tobacco exposure, and were 
HPV negative. Most (83%) of the patients with TP53 mutations 
had evidence of PAX5 methylation (Fig. S7).
Validation of PAX1, ZIC4, PLCB1, and PAX5 promoter 
methylation with quantitative methylation specific PCR and 
TCGA data
We performed qMSP for 3 genes, PAX1, ZIC4, and PLCB1, 
in 76 tumor samples previously used by Agrawal in a HNSCC 
deep sequencing study1 and 19 UPPP samples (Table S7 provides 
qMSP primers and probes information). All 3 genes appeared 
on our top ten list of TSG inactivated by both mechanisms and 
we confirmed a high frequency of tumor specific methylation 
in the Validation cohort. PAX1 was methylated in 68% of the 
cancer cases, ZIC4 in 80% and PLCB1 in 52%. We then tested 
PAX 5 because it is in the PAX gene family and appeared on the 
list of the most frequently inactivated genes by promoter meth-
ylation and downregulation of expression. PAX5 was methylated 
in 77% of the HNSCC cases in the validation cohort, a num-
ber very similar to the 70% methylation frequency identified in 
the discovery set. We found that PAX1 (P < 0.0001), ZIC4 (P < 
0.0001), PLCB1 (P < 0.001), and PAX5 (P < 0.0001) methyla-
tion distinguished tumor from UPPP samples (Figs. 4A and B). 
Figure  3. Integrative analysis of co-localized promoter methylation and somatic mutations with concurrent expression changes. (A) Methylated 
genes with fold change differences in expression greater than 2; (B) Genes with co-localized promoter methylation and somatic mutations in hNscc. 
Methylation frequency is represented by the red color. Mutation frequency is represented by the blue color. The purple color represents the combined 
frequency of methylation and mutation events in the Discovery cohort.
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Receiver Operator Characteristic (ROC) curve analysis revealed 
that PAX1 had 68% sensitivity, 90% specificity and a 0.72 AUC; 
ZIC4 had 73% sensitivity, 100% specificity, and a 0.87 AUC; 
PLCB1 had 55% sensitivity, 84% specificity, and a 0.70 AUC; 
and PAX5 had 80% sensitivity, 94% specificity, and a 0.86 AUC 
(Fig. 4C). A gene panel combining promoter methylation results 
for these four genes had 96% sensitivity, 94% specificity, a 0.97 
AUC, and a Positive Predictive Value of 98.5% (Fig. 4D). A 
chi-square test of independence revealed an association between 
methylation in PLCB1 and tumor site, P < 0.01. Tumors of the 
oral cavity and oropharynx were the most frequently methylated.
All samples harboring CDKN2A mutations had PAX1 meth-
ylation (P < 0.0001) as did most of TP53 mutated samples (P < 
0.01). More than half of NOTCH1 (61.5%, P < 0.0001) mutated 
samples also exhibited PAX1 promoter methylation. All the 
samples with mutations in FBXW7 (P < 0.0001), and most of 
the samples with mutations in TP53 (79%, P < 0.0001), and 
NOTCH1 (92%, P < 0.0001) were methylated in the PAX5 
promoter even after controlling for HPV-status and history of 
tobacco use (Table S8A).
We further corroborated our qMSP and somatic mutation 
results by analyzing The Cancer Genome Atlas (TCGA) pub-
licly available data from 279 HNSCC patients (https://tcga-data.
nci.nih.gov). PAX5 promoter methylation was associated with 
TP53 mutations (P = 0.02), while PAX1 promoter methylation 
was associated with NOTCH1 mutations (P < 0.0001), even after 
controlling for HPV-status and tobacco use. This evidence sug-
gests a frequent occurrence of previously unreported interactions 
Figure 4. qMsP results for PAX1, PAX5, ZIC4 and PLCB1. (A) Graphical expression of the logistic regression, Pr (HNSCC = 1) = logit -1 (b0 + b1 x methylation) 
in tissue from 76 participants with data overlain. The predictor methylation is the qMsP value for each case (1) and each control (0). cutoff methylation 
values for PAX1, PAX5 ZIC4 and PLCB1 are shown by the vertical dotted line. Probability of hNscc is shown in red; (B) scatterplots of quantitative MsP 
analysis of candidate genes promoters in the Validation screen cohort, which consisted of 76 hNscc tumor tissue samples and 19 normal tissue samples 
obtained from uvulopharyngopalatoplasty (UPPP) procedures performed in non-cancer patients. The relative level of methylated DNa for each gene 
in each sample was determined as a ratio of MsP for the amplified gene to acTB and then multiplied by 1000 [(average value of duplicates of gene of 
interest / average value of duplicates of acTB) x 1000] for, PAX1, PAX5, ZIC4, and PLCB1. Red line denotes cutoff value; (C) sensitivity, specificity and aUc 
results for qMsP analysis; (D) Receiver Operator characteristics (ROc) curve for promoter methylation of PAX1, PAX5, ZIC4 and PLCB1 genes in the valida-
tion cohort. The figure shows that for this four gene panel the qMsP results have 96% sensitivity, 94% specificity, a 0.97 aUc and a Positive Predictive 
Value of 98.5%.
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between PAX1 and PAX5 promoter methylation and exonic 
mutations in NOTCH1 and TP53 in HNSCC, respectively 
(Table S8B).
To provide additional evidence of expression downregulation 
of PAX1 and PAX5 in HNSCC we compared mRNA expres-
sion in HNSCC and UPPP samples. Differential transcript levels 
for PAX1 and PAX5 were confirmed by quantitative RT-PCR in 
some of the RNA samples used for microarray analysis and RNA 
samples from an independent set (Fig. S8A and B). Expression 
levels were studied in 13 HNSCC and 17 UPPP samples that 
were readily available. The relative expression levels showed con-
sistency with the results obtained for PAX1 and PAX5 in the 
Discovery cohort with genome-wide methylation and mRNA 
expression platforms.
We also performed PAX5 knock-in and knock out studies in 
p53 wild type (p53wt) and p53 mutated (p53mut) HNSCC cell 
lines to assess the role of PAX5 as a tumor suppressor gene con-
nected to the p53 pathway in HNSCC. We studied the func-
tional consequences of PAX5 induction in 022(p53wt) and 
22A(p53mut) HNSCC cell lines. Following transfection with 
(Myc-DDK-tagged)-Human paired box 5, 022 and 22A cells 
exhibited a dramatic decrease in cell proliferation and PAX5 
expression levels were significantly increased, when measured 
48h after transient transfection (Fig. S9).
Conversely, 22B(p53mut) HNSCC cells showed modest 
increase in cell proliferation compared with the control, when 
PAX5 was inhibited by siRNA following transfection with PAX5 
siRNAs. Expression levels were significantly decreased, 48h after 
transient transfection (Fig. S10).
Proposed pathway interplay
After gene set enrichment analysis revealed that concurrent 
promoter methylation, mutations, and differential gene expres-
sion impacted cell differentiation, proliferation, growth and 
renewal pathways we performed a review study of the most 
important, potentially impacted cancer pathways in HNSCC. 
We found evidence of a strong interplay between somatic muta-
tions in p53 and NOTCH1 and gene downregulation associated 
to PAX1 and PAX5 promoter methylation in HNSCC.
p53-PAX5
Our literature search revealed that p53-PAX5 interactions 
are implicated in apoptotic and/or proliferating signals. p53 is 
a downstream target for PAX proteins.26,27 The human p53 gene 
harbors a PAX binding site within its un-translated first exon 
that is conserved throughout evolution, which suggests the 
importance of this interaction. Frequent promoter methylation 
of PAX5 has been reported in ductal carcinoma in situ, invasive 
breast cancer, and neuroendocrine carcinomas.28,29 Furthermore, 
PAX5 has been reported to function as a tumor suppressor gene in 
hepatocellular carcinoma30 and gastric cancer,31 directly binding 
to the p53 promoter (Fig. S11). PAX5 also plays an important role 
in the commitment of lymphoid progenitors to the B lymphocyte 
lineage.32 The mechanism through which PAX5 acts in B-cell 
differentiation is well established.33-35 Recent studies identified 
some of these interactions also in solid tumors, but little has been 
shown so far (Fig. 5A).36-38 In our Discovery cohort we identi-
fied high frequency of PAX5 promoter methylation in HNSCC, 
coinciding with low expression levels, a finding that supports a 
TSG function.
NOTCH1-PAX1
Agrawal et al. revealed inactivating mutations in NOTCH1 
gene, depicting its importance in HNSCC, proposing also a 
tumor suppressor function in this particular type of tumors.1 
When NOTCH1 acts as a TSG it inhibits proliferation and 
promotes entry to differentiation.39 Targeting the Notch prolif-
eration pathway is really difficult. Preliminary data in cell lines 
showed that downregulation of NOTCH1 in NOTCH1 mutant 
cell lines leads to a modest effect of cell cycle acceleration and 
anti-NOTCH1 agents are only effective in NOTCH1 wild type 
cell lines.40 In our study, PAX1 was found to be the most fre-
quently methylated and downregulated gene. In addition to that, 
several HOX family genes, some of which are known to interact 
with NOTCH signaling, were prominent in our list of methylated 
genes in HNSCC (Fig. S12). Our evidence suggests an interac-
tion between NOTCH1 and PAX1 through the HOX family of 
transcription factors39,41-43 and also with the Hedgehog pathway 
through Hes1, in which the well-established CCND1 amplifica-
tion plays an important role.44-48 PAX1 plays a role in sclerotome 
differentiation and has been shown to interact with homeobox 
genes which play a prominent role in normal development and 
the control of cell proliferation.49 Retinoid acid (RA) signaling 
acts via Hox gene pathways,50,51 some of which are able to regu-
late PAX1 through canonical NOTCH1 expression. These inter-
actions are described in Figure 5B.
Discussion
We have conducted the first comprehensive integrated 
genomic and epigenomic analysis in HNSCC, focusing on identi-
fying TSG genes that demonstrate concurrent promoter methyla-
tion with downregulation of expression and somatic mutations. 
Recent studies in HNSCC, published as we were finalizing this 
manuscript, focused on therapeutic pathways affected by somatic 
mutations and copy number alterations,52-54 but only described 
the clustering effects of DNA methylation at a global genome 
wide level.52 We performed the first detailed genome wide analy-
sis of the HNSCC methylome that studied expression alterations 
associated with differential methylation patterns in the greater 
promoter region, focusing on key TSGs that are also inactivated 
by somatic mutations. The main focus of this paper was to iden-
tify the number of tumor suppressor genes differentially methyl-
ated in the greater promoter region and mutated in HNSCC, and 
examine their combined impact in expression downregulation. 
We controlled for chromosomal deletions using CNV data previ-
ously generated in the Discovery cohort, to distinguish if expres-
sion alterations were related to methylation events or to deletions 
in specific regions of the chromosome.
Many genes with dense promoter methylation and downregu-
lation of expression are candidate TSGs.  However, genes inacti-
vated by both somatic mutations and promoter methylation are 
likely to be key drivers of oncogenesis. Our analysis identified 
10 downregulated genes inactivated by somatic mutation and 
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Figure 5. Proposed genomic and epigenomic interactions in hNscc: (A) Proposed partial pathway interplay of p53 and PAX5 in hNscc. Downregulation 
of PAX5 leads to differentiation. When methylated, PAX5 an upstream target of p53, fails to activate the later which is also silenced due to mutations, and 
thus DNa repair, apoptosis, and Growth arrest pathways are inactive; (B) PAX1-NOTCH1 interplay through crosstalk of hedgehog and Notch pathways 
in cell differentiation and proliferation signals. Notch1 induces p21 expression, either directly through the canonical pathway or indirectly through Hes1 
and NFAT activation, leading in both cases to cell cycle arrest. active Notch1 targets either the Hox family or Hes1. Hes1 is active and will block differentia-
tion. The HOX family of transcription factors, downstream targets of Notch signaling, is frequently silenced, thus blocking the activation of PAX1 which 
is also downregulated in hNscc and will not promote differentiation. PAX1 expression can also be induced by Shh through Gli2, which is active. Finally, 
proliferation is promoted through Gli2 interaction with CCND1 and CCND2.
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promoter methylation. We selected PAX1, ZIC4, PLCB1, and 
PAX5 for further validation and we were indeed able to detect 
stark differences in DNA methylation levels between cancer and 
UPPP samples. ZIC4 and PLCB1 were the genes with the lowest 
methylation frequency in HNSCC, exhibiting also low mutation 
frequency, and yet, we confirmed ZIC4 and PLCB1 promoter 
methylation differences between normal and cancer samples in 
the Validation cohort.
PAX1 and PAX5 were highlighted as key genes in this study as 
they belong to the same family of transcription factors and were 
both found to be methylated and downregulated in HNSCC. 
PAX1 and PAX5 are genes involved in differentiation/prolif-
eration signals and the gene set enrichment analysis performed 
clearly depicted these signaling pathways as deregulated in 
HNSCC in our discovery set of tumors.
We observed interesting relationships among the most com-
monly mutated and methylated genes in HNSCC: 61.5% of 
the NOTCH1 mutated samples also exhibited PAX1 methyla-
tion and 79% of the samples carrying TP53 mutations were also 
methylated in the PAX5 gene promoter. External validation in 
279 primary HNSCC samples from the TCGA project verified 
our initial findings. Combined, this evidence suggests the fre-
quent occurrence of previously unreported interactions between 
PAX1 and PAX5 promoter methylation and exonic mutations in 
NOTCH1 and TP53 in HNSCC.
The greater promoter PAX1 and PAX5 methylation levels 
reported in this manuscript were obtained with three different 
platforms that use diverse technology, chemistry, sample prepara-
tion and data analysis pipelines to obtain methylation values. We 
have combined these three platforms into a very robust methyla-
tion detection pipeline.
PAX1 and PAX5 methylation levels listed in the Discovery 
cohort are both, from MBD-seq and the 450K BeadChip assay. 
The 450K results were used to confirm the MBD-seq results in 
the subset of ten Discovery samples that were sequenced and, by 
proxy, validate the methylation results of the other 22 Discovery 
cohort samples that were only queried with the 450K arrays. 
The levels of PAX1 and PAX5 methylation levels listed for the 
Prevalence cohort were obtained with quantitative methylation 
specific PCR (qMSP). The levels of PAX1 and PAX5 listed for 
TCGA were obtained with the 450K BeadChip assay. The dif-
ference in PAX1 methylation between HPV positive and HPV 
negative tumors was significant in the Discovery cohort. The 
difference between the two in the Prevalence cohort was not sig-
nificant (P = 0.225), perhaps due to the small sample size of HPV 
positive patients.
PAX genes, a family of nine transcription factors which act 
as cell lineage specific regulators of the tissues where they are 
normally expressed, are now also recognized as important factors 
in cancer progression. PAX genes, similarly to the NOTCH gene 
family, may play previously unrecognized fundamental roles in 
balancing proliferation and differentiation signals, two concep-
tually opposite cellular processes in canonical cancer research. 
The PAX family of genes may ultimately, following Waddington’s 
epigenetic landscape metaphor, be part of an epigenomic medi-
ated switch between cancer initiation and cancer maintenance 
pathways, which stochastically drive cancer progression, immune 
system avoidance, acquisition of tumor resistance, and estab-
lishment of metastatic disease. Loss of ΝOTCH1 function due 
to mutation, or mutation/methylation-dependent silencing of 
downstream genes, such as PAX1 or the HOX family genes, is 
likely to abrogate normal cell differentiation.
Clinically, TP53 mutation has been shown time and again 
to be among the worst molecular alterations in patients with 
HNSCC.36,55 Patients that harbor p53 mutant tumors are more 
likely to relapse after complete resection and radiation therapy.5 
We confirmed a high frequency of PAX methylated tumors in 
279 HNSCC tumor samples from the TCGA cohort and found 
that tumors which already harbor a p53 mutation, also harbor 
PAX5 promoter methylation.
Together, our results support the notion that differential pro-
moter methylation and somatic mutations are the main cause 
of gene inactivation and pathway deregulation in HNSCC. We 
have unveiled hitherto unknown interactions between mutated 
and methylated genes that are associated with gene expres-
sion alterations in HNSCC. Characterization of the complete 
HNSCC methylome has contributed insights into the clustering 
of specific genetic and epigenetic events in the greater promoter 
region and highlights the importance of understanding the rela-
tive contribution of each to the overall frequency of TSG inacti-
vation. We plan future in vitro studies focused on the functional 
consequences of the inactivation of these high frequency genes 
and will further explore the above proposed gene interactions. 
Understanding the complete contribution of genomic and epig-
enomic alterations to specific genes and pathways in cancer will 
reveal novel high frequency specific markers for better risk assess-
ment (as we observed in the TCGA cohort above) and will high-
light the true frequency of therapeutic pathways to better target 




Head and Neck Squamous Cell Carcinoma (n = 91) and uvulo-
palatopharyngealplasty (UPPP) patients (n = 35) were consented 
for this study at the Johns Hopkins Medical Institutions hospitals 
and MD Anderson Cancer Center. The study was approved by 
the Ethics Committee of each participating hospital, as well as by 
the Johns Hopkins Institutional Review Board.
Johns Hopkins component
Fresh-frozen surgically resected tissue and matched blood were 
obtained from patients at Johns Hopkins Medical Institutions 
in Baltimore. Tissue was analyzed by frozen section histology 
to estimate neoplastic cellularity. In order to enrich the samples 
for neoplastic cells, normal tissue was removed from the samples 
using macro-dissection based on the frozen section histology. 
HPV tumor status was determined for oropharyngeal tumors per 
standard clinical care using in situ hybridization. Hybridization 
was performed using the HPV III Family16 probe set that cap-
tures HPV genotypes 16, 18, 33, 35, 45, 51, 52, 56, and 66. 
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HPV16-positive controls included an HPV16-positive oropha-
ryngeal cancer and the SiHa and CaSki cell lines. HPV tumor 
status was also determined by E6/E7 PCR primer amplification.
MD Anderson Component
Fresh-frozen surgically resected tumor and matched non-
malignant adjacent tissue were obtained from consented patients 
treated for HNSCC at the University of Texas MD Anderson 
Cancer Center, under an Institutional Review Board approved 
protocol. Frozen tissue was embedded in optimal cutting tem-
perature compound and cryosections from the top and middle 
of specimens were stained with hematoxylin and eosin prior to 
being evaluated by a pathologist for the presence of >60% tumor 
nuclei content or absence of tumor (i.e., normal). Samples that 
passed this criterion were sectioned all the way through and 
washed once in PBS prior to isolating genomic DNA using an 
ArchivePure DNA purification kit.
Methylated binding domain sequencing (MBD-seq)
Preparation of libraries
Tissue samples were digested with 1% SDS and 50 μg/mL 
proteinase K (Boehringer Mannheim) at 48 °C overnight, fol-
lowed by phenol/chloroform extraction and ethanol precipitation 
of DNA. Two micrograms of DNA were sonicated to a modal size 
of ~150–250 bp, and end-repaired using the NEBNext SOLiD 
DNA library preparation kit end-repair module following the 
manufacturer’s protocol (New England Biolabs). After column-
purification (using the Qiagen PCR purification kit), SOLiD P1 
and P2 adapters lacking 5′ phospate groups (Life Technologies) 
were ligated using the NEBNext adaptor ligation module and 
column-purified, and subjected to nick-translation by treating 
with Platinum Taq polymerase to remove the nick.
Affinity enrichment and capture of methylated DNA fragments
The resulting library was divided into two fractions, a total 
input fraction, and an enriched methylated fraction. The enriched 
methylated fraction was then subjected to affinity enrichment 
of methylated DNA fragments by using 6xHis-MBD2-MBD 
polypeptides immobilized on magnetic beads as described pre-
viously.56,57 The resulting enriched methylated fraction and the 
total input fraction were then subjected to library amplifica-
tion using the NEBNext amplification module according to the 
manufacturer’s protocols, using 4–6 cycles for the total input, 
and 10–12 cycles for the enriched methylated fractions. Library 
fragments that were between 200–300 bp were size selected after 
agarose gel electrophoresis.
Massively parallel sequencing of MBD-seq libraries
The libraries were then subjected to emulsion PCR and bead 
enrichment following the SOLiD emulsion PCR protocol (Life 
Technologies). The resulting beads were then deposited on the 
SOLiD flow cell and subjected to massively parallel 50 bp single-
read sequencing on a SOLiD v4.0 sequencer octet segment, with 
one octet segment for the total input and another one for the 
enriched methylated fraction. The details of the sequencing out-
put for each sample from the sequencing run (number of tags, 
coverage, etc.) are provided in Table S9. Reads were aligned to 
hg19 using default settings in bioscope v1.3, with the exception of 
the bam output method, which was changed to alignment score.
Bioinformatics analysis of MBD-seq data
MACS analysis and identification of differential methylation
For the purposes of the analysis we divided the genome 
into two broad regions: the greater promoter, was defined as 
the region encompassing 6000 bases upstream and 1500 bases 
downstream from the transcription start site (TSS). From the 
functional genome distribution standpoint the greater promoter 
region, includes CpG sites in the proximal promoters, 1500 bases 
upstream from the described TSS, and 1500 bases downstream 
from the TSS, in the 5′ untranslated region and exon1. From 
the CpG content and neighborhood context the differentially 
methylated CpGs in HNSCC were located in CpG islands, CpG 
shores (regions 2000 bp upstream and downstream of but not 
inside CpG islands), CpG shelves (regions 2000 bp upstream and 
downstream of but not inside the shores), or as isolated CpGs in 
the area of the genome now defined as Open Sea. Methylated 
regions were identified as peaks of aligned sequencing tags in 
the enriched compared with total input fraction using MACS 
v1.4 software,22,58,59 which allows identification of peaks after 
accounting for both global and local biases using the total input 
fraction. Peaks of methylation were identified for each sample 
separately.
To identify differentially methylated regions we first used 
stringent parameters to define presence and absence of methyla-
tion in EACH sample as follows: we used a low MACS P value 
cut-off (P < 10–6) to identify regions that are methylated, and 
another cut-off (MACS P > 10–2) to identify those regions that 
have very little evidence for methylation.
Next, for any given comparison of group A vs. group B (e.g., 
Group A = all tumors; Group B = all normals), we identified 
all regions that showed absence of methylation in all samples of 
Group A and presence of methylation in at least one sample from 
group B. All such overlapping regions across samples with peak 
calls in Group B were then merged, and the number of such sam-
ples and the lowest p-value of the peaks for these samples were 
recorded as the aggregate differentially methylated region. This 
analysis therefore yields regions in which all samples in Group 
A have absence of methylation peaks, and at least one sample 
in Group B has a methylation peak. The converse comparisons 
(i.e., absence of methylation in Group B, with at least one sample 
having a methylation peak in Group A) were also performed to 
obtain regions showing both gain of- and loss of-methylation.
Methylation bumphunting for identification of differentially 
methylated regions
Differential methylation was also identified using an indepen-
dent approach called bumphunting that has been previously used 
to identify differential peaks in methylation data. Methylation 
bumphunting is a data analysis pipeline that effectively mod-
els measurement error, removes batch effects, detects regions of 
interest and attaches statistical uncertainty to regions identified 
as differentially methylated.23 These methods are implemented 
in the bumphunter Bioconductor package and described in more 
detail in the section “Bioinformatics for 450K data.” Reported 
functionally relevant findings have been generally associated with 
genomic regions rather than single CpGs, either CpG islands,60 
CpG island shores,20 genomic blocks,61 or generic 2-kb regions.62 
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Epigenomic bumps may have greater variability in size and shape 
than MBD-seq peaks.
Integration of MACS and bumphunting results
To identify the promoter regions that are differentially meth-
ylated in HNSCC when compared with normal oral mucosa, 
we intersected the list of methylated probes that discriminated 
between tumor and normal tissue identified with MACS with 
the list of methylated regions that discriminated between tumor 
and normal tissue identified with bumphunting. We used R 
(v3.00) to analyze the correlation of methylated promoter regions 
and HNSCC etiological factors.
Verification of MBD-seq results with 
HumanMethylation450K DNA BeadChip assay
450K array description and sample preparation
The 450K is a two-color array that detects cytosine methyla-
tion at 485, 512 methylation loci, mostly at CpGs, but also at a 
small number of cytosine residues outside of the CpG context, 
using bisulfite converted DNA. For each individual CpG two 
different signals are detected. One signal measures the amount of 
methylated DNA (Meth) and the other one measures the amount 
of unmethylated DNA (Unmeth). The Meth and Unmeth signals 
are measured with two different assays called “Type I” design or 
a “Type II” design. A β (β) value is generated by both Type I and 
Type II design probes to denote the methylation level of the CpG 
loci using the ratio of intensities between Meth and Unmeth 
(β value = methylation intensity / methylation + unmethyl-
ated intensity of the given CpG locus). Each methylation locus 
is interrogated by one of these designs. For a type I locus the 
Meth and Unmeth signals are measured by two paired probes, 
with a given locus using either the red or green signal from these 
probes. Type II loci are assayed using a single probe, with Meth 
and Unmeth signals derived from the green and red channels 
respectively. In addition to the methylation loci, the array con-
tains a small number of control probes and 65 probes measuring 
common SNPs, intended for sample tracking. Type II probes use 
only one probe per methylation locus and hence allows more loci 
on the array, at a fixed array size. However, due to the chemistry 
used by the type II probe design, type II probes can only toler-
ate up to three CpGs within the 50bp probe. The type I design 
tolerates more CpGs within the 50bp probe, but assumes that all 
methylation loci in the probed sequence are in the same state.63
Bisulfite modification of genomic DNA (2 μg) was performed 
with EpiTect Bisulfite Kit (QIAGEN) according to the manufac-
turer’s protocol. We hybridized bisulfite converted DNA from 
normal (UPPP) tissue (n = 16) and Head and Neck Squamous 
Cell Carcinoma (HNSCC) tissue (n = 31) samples to the 450K 
array.
Bioinformatics for 450K data
Bioinformatics strategies were used for background correc-
tion, normalization, and data analysis of differentially methyl-
ated genomic regions between tumor, and normal tissue. As with 
the analysis of methylation sequencing data we used two differ-
ent analytic pipelines: a pipeline designed to capture the vari-
ability in methylated signals across the arrays using an F-test11 
and the bumphunting pipeline.23 We used the minfi and bump-
hunter packages found in Bioconductor to perform background 
correction, normalization, and data analysis of differentially 
methylated genomic regions between tumor and normal tis-
sue. The minfi package provides tools for analyzing Illumina’s 
Methylation arrays, with a special focus on the new 450k array 
for humans, and includes methods for preprocessing, quality 
assessment, and detection of differentially methylated regions 
from the kilobase to the megabase scale.64 The bumphunter pack-
age is meant to work on data with several biological replicates, 
similar to the lmFit function in limma. While bumphunter is 
written using genomic data as an illustrative example, most of it 
is generalizable to other data types (with some one-dimensional 
location information).
F-test analytic pipeline
The selection of significantly methylated CpGs in the Illumina 
450K Infinium assay data was performed in a stepwise manner. 
The 450.idat files were preprocessed and background corrected 
with the preprocessIllumina function in minfi to obtain β values. 
An F-test was performed across all 47 samples to identify CpGs 
with a significant difference in β values between normal and 
malignant tissue. Since the empirical P values were calculated 
genome-wide, adjustment for multiple testing was performed. 
Q-values were computed from the empirical P values using the 
Benjamin and Hochberg correction. Probes with q-values less 
than 0.05 were deemed statistically significant and were included 
in the CpG list. We then selected only those CpGs that showed 
a methylation difference of at least 0.25 between cancer and nor-
mal tissues and a β value of at least 0.3 in cancer, as previously 
described.11 All bioinformatics analyses were performed using R 
version 3.0.
450K-bumphunting analytic pipeline
We performed pre-processing with the minfi package, which 
applies a version of subset quantile normalization to the Meth 
and Unmeth intensities separately. The distribution of type I and 
type II probes is forced to be the same by first quantile normal-
izing the type II probes across samples and then interpolating 
a reference distribution to which the type I probes are normal-
ized. For the probes on the X and Y chromosomes the males 
and females are normalized separately. Sex is determined by the 
getSex function using copy number information. The stratified 
quantile normalization method is implemented by the prepro-
cessQuantile function (the function does no background correc-
tion and removes zeros using the fix2 MethOutlier function). 
This algorithm relies on the assumptions necessary for quantile 
normalization and involves both within- and between- sample 
normalization.64
Integration of F-test and 450K-bumphunting results
To identify the promoter regions that are differentially meth-
ylated in HNSCC when compared with normal oral mucosa, 
we intersected the list of methylated probes that discriminated 
between tumor and normal tissue identified with the F-test with 
the list of methylated regions that discriminated between tumor 
and normal tissue identified with 450K-bumphuntig.
E. mRNA expression arrays
Total RNA was isolated from normal (UPPP) tissue (n = 16) 
and Head and Neck Squamous Cell Carcinoma (HNSCC) tis-
sue (n = 16) samples by using Tri-reagent. cDNA was made, and 
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hybridized to Affymetrix GeneST1.0 Arrays (Affymetrix) accord-
ing to manufacturer’s instructions. Six of these samples were also 
sequenced with MDB-seq. The data obtained from CEL files was 
background corrected with RMA, quantile normalized before an 
ANOVA was used to determine the Fold Change difference in 
log-transformed intensities between Tumor and Normal samples.
Analysis of functional annotation
Enrichment analysis of functional themes (Analysis of 
Functional Annotation, AFA) was performed to capture biologi-
cal processes over-represented in the various conditions under 
investigation. This unbiased computational approach, con-
ceptually similar to Gene Set Enrichment Analysis (GSEA),65 
enables the interpretation of genome-wide data through the 
identification and visualization of information encompassing 
distinct biological concepts, and was previously used success-
fully to integrate and interpret both differential gene expression 
and methylation data.25,66 A chi-square test of independence was 
applied to test whether each Functional Gene Set (FGS) was 
over-represented in any of the gene list associated with any of 
the investigated contrasts/conditions (e.g., gene associated with 
methylated promoters in HNSCC). In the present study, indi-
vidual, non-redundant genes, as annotated in the NCBI Entrez 
gene database (R/Bioconductor package org.Hs.eg.db version 
2.4.6) were used as the total gene space, and contingency tables 
were used to identify gene sets over-represented in the investi-
gated conditions. Correction for multiple hypothesis testing was 
obtained separately for each FGS collection, by applying the 
Benjamini and Hochberg method67 as implemented in the mult-
test R/Bioconductor package. Overall, this approach is analo-
gous to Gene Set Enrichment Analysis (GSEA),65,68,69 and has 
already been successfully applied in other studies.66,70 The heat-
maps’ color bar represents the negative log10 False Discovery 
Rate (FDR). For each gene set collection the sets for which at 
least one condition showed FDR < 0.01 were reported. The top 
150 conditions were reported when too many gene sets where 
retrieved.
AFA was used to compare biological themes enriched in the 
following gene lists: (1) mutated genes; (2) genes with hyper-
methylated promoters; (3) genes showing hyper-methylation 
outside the greater promoter region; (4) genes upregulated in 
cancer when compared with normal; and (5) genes downregu-
lated in cancer when compared with normal. Gene set enrich-
ment was assessed by testing for gene set over-representation 
with a chi-square test, because each gene list was obtained from 
diverse analyses using different methods. In the AFA analysis 
each gene was counted only once, while using the totality of 
the genes annotated to the NCBI Entrez gene database as the 
background gene space. For this reason there was no confound-
ing with the number of probes or the length of the genes (i.e., 
each gene was counted only once irrespective to the number of 
probes or its length). The GO categories reported in Table S6 
encompass different biological processes and contain a fairly 
large number of distinct genes. Such genes show variable length, 
from short to long transcripts, and all possible and disparate 
genomic arrangements, with genes located in both “gene-rich” 
and “gene-poor” genomic regions.
Validation of genomic and epigenomic alterations
Quantitative methylation specific PCR (qMSP) in the prevalence 
cohort
qMSP was used for validation in a Prevalence cohort of 76 
tumors in which we had previously identified somatic mutations 
in TP53, NOTCH1, CDKN2A, PIK3CA, FBXW7, and HRAS 
and in 19 UPPP normal control tissue samples. We examined 
promoter methylation in three of the genes that were included 
in our final list of mutated and methylated genes and that were 
methylated in at least 40% of the Discovery Cohort samples: 
PAX1, PAX5, PLCB1, and ZIC4. Bisulfite-modified DNA was 
used as a template for fluorescence-based real-time PCR, as pre-
viously described.71
Contingency tables of mutational and methylation events in 
TCGA data set
Publicly available HNSCC Illumina 450K methylation and 
exome sequencing data was downloaded from the TCGA web-
site (http://cancergenome.nih.gov) and the cBioPortal for Cancer 
Genomics (www.cbioportal.org/public-portal/) using R (v3.0.0). 
Publicly available exome mutation data for TP53 and NOTCH1 
and β values for all PAX1 and PAX5 450K array probes were 
extracted for all HNSCC samples analyzed by the TCGA project 
that had paired methylation and mutation data for the genes of 
interest (n = 279). Only the 450K probes located in TSS1500, 
TSS200, and 1st exon, as per the manufacturer’s annotation, 
were used to create the contingency tables for methylation and 
mutation analyses. Contingency tables were used to examine 
the association between exonic mutations of TP53, CDKN2A, 
HRAS, FBXW7, and NOTCH1 and promoter methylation of 
ZIC4, PAX1, PAX5, and PLCB1. The MacNemar test for paired 
data was implemented in R (v3.0.0) to evaluate the association 
between mutations and promoter methylation.
Quantitative real-time reverse transcription PCR
HNSCC RNA samples from the Discovery cohort and from 
an independent cohort were assessed for PAX5, PAX1, and 
GAPDH expression levels using quantitative real-time reverse 
transcription (RT)-PCR (TaqMan). Reverse transcription was 
performed with random hexamer primers and Superscript II 
Reverse Transcriptase (Invitrogen Corp.) according to manufac-
turer’s instructions. Quantitative RT-PCR was then performed 
on the Applied Biosystems 7900 Sequence Detection Instrument 
(Applied Biosystems) using TaqMan expression assays (Life 
Technologies).
Functional studies in cell lines
Human HNSCC cell lines with known p53 status were cul-
tured to determine PAX5 methylation and expression levels. 
Human HNSCC cell lines 022 (p53 wt), 22A (p53 mut), and 
22B (p53 mut) were selected for functional studies based on their 
expression and methylation results (Fig. S13). Cell growth condi-
tions were maintained at 37 °C in an atmosphere of 5% CO2.
Transient transfection, PAX5 inhibition or overexpression, 
and cell proliferation assay
We knocked down PAX5 in the 22B cell line using the 
ON-TARGETplus Pool of siRNAs against PAX5 and a non-tar-
geting Pool of siRNAs (Thermo Scientific) as control. Cells were 
seeded in 96-well plates and allowed to grow until approximately 
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